ESPR [NASD]
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-6.98 Insider Own0.80% Shs Outstand60.95M Perf Week25.67%
Market Cap346.78M Forward P/E- EPS next Y-1.63 Insider Trans-0.17% Shs Float18.84M Perf Month26.20%
Income-234.90M PEG- EPS next Q-0.93 Inst Own88.50% Short Float46.60% Perf Quarter52.51%
Sales89.30M P/S3.88 EPS this Y-78.20% Inst Trans1.78% Short Ratio6.13 Perf Half Y-28.67%
Book/sh-4.09 P/B- EPS next Y62.40% ROA-76.40% Target Price10.85 Perf Year-70.32%
Cash/sh3.82 P/C1.59 EPS next 5Y16.90% ROE84.40% 52W Range3.28 - 26.77 Perf YTD21.40%
Dividend- P/FCF- EPS past 5Y-22.90% ROI-369.30% 52W High-76.88% Beta0.44
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin78.10% 52W Low88.72% ATR0.50
Employees218 Current Ratio3.70 Sales Q/Q135.00% Oper. Margin- RSI (14)58.05 Volatility10.30% 9.01%
OptionableYes Debt/Eq- EPS Q/Q73.40% Profit Margin- Rel Volume0.56 Prev Close6.07
ShortableYes LT Debt/Eq- EarningsMay 03 BMO Payout- Avg Volume1.43M Price6.19
Recom2.80 SMA2010.85% SMA5016.56% SMA200-16.98% Volume310,240 Change1.98%
May-05-22Upgrade JP Morgan Underweight → Neutral $6
Mar-10-22Initiated H.C. Wainwright Buy $22
Oct-19-21Downgrade Credit Suisse Outperform → Neutral $28 → $11
Oct-14-21Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $11
May-05-21Downgrade Stifel Buy → Hold $37 → $20
Apr-26-21Resumed Credit Suisse Outperform $45
Mar-11-21Initiated Morgan Stanley Equal-Weight $30
Feb-12-21Downgrade Jefferies Buy → Hold $30
Feb-09-21Downgrade Goldman Neutral → Sell $44 → $24
Jan-15-21Downgrade BofA Securities Buy → Neutral $52 → $35
Nov-10-20Upgrade Credit Suisse Neutral → Outperform $45
Sep-29-20Resumed JP Morgan Underweight $35
Aug-11-20Downgrade Credit Suisse Outperform → Neutral $83 → $45
Apr-01-20Resumed BofA/Merrill Buy $50
Mar-17-20Upgrade Citigroup Neutral → Buy
Feb-24-20Downgrade Northland Capital Outperform → Market Perform $60
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
May-17-22 08:00AM  
May-13-22 10:28AM  
May-04-22 10:52AM  
May-03-22 02:00PM  
08:25AM  
07:00AM  
May-02-22 03:55PM  
08:00AM  
Apr-29-22 05:00PM  
10:00AM  
Apr-28-22 04:00PM  
Apr-26-22 03:01PM  
Apr-25-22 08:00AM  
Apr-19-22 07:00AM  
Apr-14-22 10:06AM  
Apr-13-22 08:00AM  
Apr-11-22 01:31PM  
Apr-08-22 03:17PM  
Apr-03-22 12:00PM  
Mar-29-22 08:00AM  
Mar-24-22 11:30AM  
Mar-16-22 06:35AM  
Feb-24-22 08:00AM  
Feb-23-22 11:54AM  
Feb-22-22 02:00PM  
08:15AM  
07:00AM  
Feb-15-22 03:01PM  
Feb-08-22 08:00AM  
Jan-28-22 05:00PM  
Jan-11-22 08:00AM  
Jan-06-22 08:00AM  
Jan-05-22 01:38PM  
04:34AM  
Jan-04-22 08:00AM  
Dec-07-21 04:05PM  
Dec-02-21 11:40PM  
05:00PM  
11:31AM  
Nov-19-21 02:05PM  
Nov-12-21 07:00AM  
Nov-06-21 09:56AM  
Nov-02-21 04:30PM  
10:57AM  
08:45AM  
07:00AM  
Nov-01-21 04:01PM  
07:00AM  
Oct-27-21 04:01PM  
Oct-26-21 03:02PM  
Oct-25-21 05:51PM  
07:00AM  
Oct-19-21 10:43AM  
Oct-18-21 05:54PM  
11:38AM  
07:59AM  
07:00AM  
Oct-12-21 08:00AM  
Sep-24-21 09:33AM  
Sep-09-21 10:50AM  
Sep-08-21 12:40PM  
Sep-07-21 04:01PM  
Sep-02-21 11:31AM  
Aug-26-21 08:00AM  
Aug-08-21 05:48AM  
Aug-04-21 10:25AM  
Aug-03-21 08:00PM  
08:55AM  
07:00AM  
Aug-02-21 01:07PM  
Jul-30-21 11:46AM  
Jul-27-21 03:03PM  
08:00AM  
Jul-13-21 08:00AM  
Jul-01-21 05:00PM  
Jun-28-21 07:59AM  
Jun-03-21 11:31AM  
May-24-21 08:00AM  
May-17-21 09:01AM  
May-15-21 12:00PM  
May-09-21 03:42AM  
May-06-21 08:00AM  
May-05-21 06:30PM  
10:28AM  
May-04-21 09:00PM  
05:55PM  
04:01PM  
02:30PM  
Apr-28-21 04:05PM  
Apr-27-21 08:00AM  
Apr-26-21 04:07PM  
04:02PM  
Apr-12-21 04:01PM  
Apr-06-21 08:00AM  
Apr-02-21 10:27AM  
Mar-25-21 11:30AM  
Mar-17-21 04:05PM  
Feb-26-21 11:55AM  
Feb-24-21 03:02AM  
Feb-23-21 05:15PM  
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Warren EricChief Commercial OfficerMay 17Sale5.981961,17253,910May 18 04:30 PM
Koenig Sheldon L.President and CEOMar 17Sale4.585712,615194,717Mar 18 04:29 PM